Find Unlimited Emails.For Free.
Discover prospects, find their business emails, and build your pipeline with Unifers.
Start for FreePatrick Garrouste
Directeur Exécutif @Debiopharm
Signup · Get unlimited contacts
WORK HISTORY
Directeur Exécutif @Debiopharm
CH
Management of a multidisciplinary team dedicated to oncology and antibiotic field. Our research is focused on : Drug Improvement, Drug Delivery and Drug Targeting. Competences of the team :Drug Research : medicinal chemistry and root scoutingResearch & Development : cover PLGA based drug delivery of API and solving problems of Bioavability of BCS class II API (nanosizing, solid disperson, lipidic formulation.)Analytical & Bio Research : drug substance and drug product characterization (physico-chemical and biological)Development of proprietary technologies for ADC (MultilinkTM and AbYlinkTM)
EDUCATION
IMD
Driving Strategic Innovation
University of Lausanne - UNIL
Post-Doc, chemoselective ligation of peptides
University of Montpellier
Ph D Thesis, master in biochemistry and Thesis in bio-organic chemistry (peptide and pseudopeptide field)
SKILLS
ABOUT PATRICK GARROUSTE
MSc in Biochemistry and Ph.D. in Bioorganic Chemistry at the Université des Sciences et Techniques du Languedoc (USTL) in Montpellier, France (1995). During the thesis, I achieved the synthesis and the physical characterization of linear and cyclic pseudopeptidic inhibitors of the HIV protease.Post doctoral position at the Institute of Organic Chemistry, Lausanne, Switzerland, as a Post-doc (19••••98): synthesis and characterization of several TASP molecule using the “chemoselective” reaction of unprotected peptide.1998 to 2004 : Analytical Development Manager in the Pharmaceutical Development Department at Debio RP (Debio group, Martigny, Switzerland). 2004 to 2015 : Pharmaceutical Development Director in the same group.From 2015 : Drug Research and Development Director at DebiopharmSpécialisations : Development of in vitro dissolution test for sustained release formulation (from 1 to 6 month of release)validation of analytical methods according to GMP rulesPeptide chemistryDevelopement of SR PLGA based formulation (from 1 week to 6 months)Delivery of API BCSII (poor solubility)
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.